How Tempus is Battling Cancer

Tempus Labs is revolutionizing the way companies do cancer treatment. Founded by Eric Lefkofsky, Tempus has become one of the top tech start ups in just a short period of time. Tempus has worked closely with National Cancer Institute’s cancer centers across the nation. Tempus has gained success by using a variety of treatment types which includes RNA sequencing, liquid biopsy, medical imaging and immune system characterization.

Tempus has earned lots of praise for their work. The company recently made Eric Topol’s list, an annual feature that recognizes great advances in the world of technology. Tempus has also been recognized for specific advances in groundbreaking technology. The company has used both gene therapy and gene editing, both of which have helped to treat sickness that was otherwise untreatable. Specifically, Voretigene neparvovec-rzyl was approved by the FDA as a treatment for rare blindness. Other advances Tempus is responsible for include advances in skin cancer treatment and pathogen sequencing technology. The success of this company has allowed it raise nearly 150 million dollars in funding.

Eric Lefkofsky is both the founder and CEO of Tempus. Lefkofsky and his company are determined to fight and defeat cancer. Lefkofsky is a businessman with an impressive resume. He has held a variety of leadership positions including founding partner of Lightbank, co-founded Inner Workings and the founder of Groupon. A Michigan native, Lefkofsky comes from a family that believes in hard work. Those values have pushed him to great success.

Eric Lefkofsky is more than just a typical success story. He is a man who believes in giving back. Along with his wife, he founded the Lefkofsky Foundation, a group committed to several educational causes. He has served on the the board of directors of The Art Institute of Chicago as well as board of directors of The Museum of Science and Industry. Lefkofsky is committed to helping others and should continue having success for years to come.

For More info: